Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>

Salvato in:
Dettagli Bibliografici
Autore principale: Stephanie Lheureux (16797697) (author)
Altri autori: Stephenie D. Prokopec (16797700) (author), Leslie E. Oldfield (16797703) (author), Eduardo Gonzalez-Ochoa (16375918) (author), Jeffrey P. Bruce (16797706) (author), Derek Wong (15135437) (author), Arnavaz Danesh (15135449) (author), Dax Torti (15135467) (author), Jonathan Torchia (16797709) (author), Alexander Fortuna (16797712) (author), Sharanjit Singh (16797715) (author), Matthew Irving (16797718) (author), Kayla Marsh (15135470) (author), Bernard Lam (15051558) (author), Vanessa Speers (16797721) (author), Aleksandra Yosifova (16797724) (author), Ana Oaknin (14956029) (author), Ainhoa Madariaga (15129719) (author), Neesha C. Dhani (16797727) (author), Valerie Bowering (16797730) (author), Amit M. Oza (15129737) (author), Trevor J. Pugh (14940894) (author)
Pubblicazione: 2025
Soggetti:
Cancer
Methods and Technology
Computational Methods
Sequence analysis
Gynecological Cancers
Ovarian cancer
Liquid Biopsy
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
Descrizione
Riassunto:<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>

Documenti analoghi